Research article summary (published 11 Oct 2009):

Relationships between biomarkers in aging and dementia.

Full Abstract

BACKGROUND: PET imaging using [(18)F]fluorodeoxyglucose (FDG) and [(11)C]Pittsburgh compound B (PIB) have been proposed as biomarkers of Alzheimer disease (AD), as have CSF measures of the 42 amino acid beta-amyloid protein (Abeta(1-42)) and total and phosphorylated tau (t-tau and p-tau). Relationships between biomarkers and with disease severity are incompletely understood. METHODS: Ten subjects with AD, 11 control subjects, and 34 subjects with mild cognitive impairment from the Alzheimer's Disease Neuroimaging Initiative underwent clinical evaluation; CSF measurement of Abeta(1-42), t-tau, and p-tau; and PIB-PET and FDG-PET scanning. Data were analyzed using continuous regression and dichotomous outcomes with subjects classified as "positive" or "negative" for AD based on cutoffs established in patients with AD and controls from other cohorts. RESULTS: Dichotomous categorization showed substantial agreement between PIB-PET and CSF Abeta(1-42) measures (91% agreement, kappa = 0.74), modest agreement between PIB-PET and p-tau (76% agreement, kappa = 0.50), and minimal agreement for other comparisons (kappa <0.3). Mini-Mental State Examination score was significantly correlated with FDG-PET but not with PIB-PET or CSF Abeta(1-42). Regression models adjusted for diagnosis showed that PIB-PET was significantly correlated with Abeta(1-42), t-tau, and p-tau(181p), whereas FDG-PET was correlated only with Abeta(1-42). CONCLUSIONS: PET and CSF biomarkers of Abeta agree with one another but are not related to cognitive impairment. [(18)F]fluorodeoxyglucose-PET is modestly related to other biomarkers but is better related to cognition. Different biomarkers for Alzheimer disease provide different information from one another that is likely to be complementary.

Author information

Author/s: Jagust, W J (WJ); Landau, S M (SM); Shaw, L M (LM); Trojanowski, J Q (JQ); Koeppe, R A (RA); Reiman, E M (EM); Foster, N L (NL); Petersen, R C (RC); Weiner, M W (MW); Price, J C (JC); Mathis, C A (CA); Alzheimer's Disease Neuroimaging Initiative;

Affiliation: Helen Wills Neuroscience Institute, University of California, Berkeley, CA 94620, USA. jagust(-atsign-)berkeley.edu

Grants: AG 024904 (Agency:NIA NIH HHS) ; AG 16574 (Agency:NIA NIH HHS) ; AG018402 (Agency:NIA NIH HHS) ; AG024904 (Agency:NIA NIH HHS) ; AG024904-S03 (Agency:NIA NIH HHS) ; AG027859 (Agency:NIA NIH HHS) ; AG027984 (Agency:NIA NIH HHS) ; AG027998-01A1 (Agency:NIA NIH HHS) ; AG06786 (Agency:NIA NIH HHS) ; MH070729 (Agency:NIMH NIH HHS) ; MH082463 (Agency:NIMH NIH HHS) ; NS060184 (Agency:NINDS NIH HHS) ; P01AG012435 (Agency:NIA NIH HHS) ; P01AG19724 (Agency:NIA NIH HHS) ; P41 RR023953 (Agency:NCRR NIH HHS) ; P50AG23501 (Agency:NIA NIH HHS) ; R01 AG022394 (Agency:NIA NIH HHS) ; R01 AG031581-10 (Agency:NIA NIH HHS) ; R01 AG10897 (Agency:NIA NIH HHS) ; R01 NS031966 (Agency:NINDS NIH HHS) ; R24 RR021992 (Agency:NCRR NIH HHS) ; T32 NS07222 (Agency:NINDS NIH HHS) ; U01 AG024904 (Agency:NIA NIH HHS) ; U01 AG10483 (Agency:NIA NIH HHS) ; U01AG024904 (Agency:NIA NIH HHS)

Journal and publication information

Publication Type: Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.

Journal: Neurology (Neurology), published in United States. (Language: eng)

Reference: 2009-Oct; vol 73 (issue 15) : pp 1193-9

Dates: Created 2009/10/13; Completed 2009/11/04;

PMID: 19822868, status: MEDLINE (last retrieval date: 11/4/2009, IMS Date: )

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Aged Aging - metabolism Alzheimer Disease - metabolism; radionuclide imaging Amyloid beta-Protein - cerebrospinal fluid Aniline Compounds - metabolism Biological Markers - cerebrospinal fluid; metabolism Brain - metabolism; radionuclide imaging Case-Control Studies Cognition Disorders - diagnosis; metabolism; radionuclide imaging

Female Fluorodeoxyglucose F18 - metabolism Humans Male Peptide Fragments - cerebrospinal fluid Positron-Emission Tomography Psychiatric Status Rating Scales Thiazoles - metabolism tau Proteins - cerebrospinal fluid

Associated Chemicals: 2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole (0) ; Amyloid beta-Protein (0) ; Aniline Compounds (0) ; Biological Markers (0) ; Peptide Fragments (0) ; Thiazoles (0) ; amyloid beta-protein (1-42) (0) ; tau Proteins (0) ; Fluorodeoxyglucose F18 (63503-12-8)

Related articles

These are the highest related articles currently in the database:

• Cerebral acetylcholine esterase activity in mild cognitive impairment. 6 Sep 2005
• PET of brain amyloid and tau in mild cognitive impairment. 19 Dec 2006
• Cerebrospinal fluid levels of amyloid beta-peptide1-42, but not tau have positive correlation with brain glucose metabolism in humans. 6 Oct 1999
• Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. 30 Mar 2005
• Reduced cerebral glucose metabolism in patients at risk for Alzheimer's disease. 21 May 2007
• Individual cerebral metabolic deficits in Alzheimer's disease and amnestic mild cognitive impairment: an FDG PET study. 15 Apr 2008
• Clinical correlates of PET- and SPECT-identified defects in dementia. 30 Oct 1994
• Association of elevated phospho-tau levels with Alzheimer-typical 18F-fluoro-2-deoxy-D-glucose positron emission tomography findings in patients with mild cognitive impairment. 13 Aug 2004
• Cube copying test in combination with rCBF or CSF A beta 42 predicts development of Alzheimer's disease. 4 Jun 2008
• Functional imaging predicts cognitive decline in Alzheimer's disease. 29 Jun 1996

See 100+ related articles.

Related Article Map

Legend: - FREE Full text Article. - Abstract only. - Title only. More help.

See a large map of 100+ related articles.